KRAS and non-small cell lung carcinoma: Although it was long thought that such KRAS mutations were undruggable, recent drug discovery efforts have resulted in Federal Drug Administration approval of sotorasib (AMG-510), a specific KRAS G12C inhibitor for patients with locoregionally advanced metastatic NSCLC.